Braze Inc
Change company Symbol lookup
Select an option...
BRZE Braze Inc
MGF MFS? Government Markets Income
LI Li Auto Inc
APAC Stonebridge Acquisition Corp
KAJMF Kajima Corp
TALKW Talkspace Equity Warrant Exp 21 June 2025 *W EXP 06/21/2025
GCTK GlucoTrack Inc
SIVBP SVB Financial Group
CYBR Cyberark Software Ltd
DD Dupont De Nemours Inc
Go

Company profile

Braze, Inc. is a provider of customer engagement platform that enables customer-centric interactions between consumers and brands. Its platform helps brands to listen to their customers, understand them and act on that understanding in a way that is human and personal. Using the Company’s platform, brands ingest and process customer data in real time, orchestrate and optimize contextually relevant, cross-channel marketing campaigns and continuously evolve their customer engagement strategies. Its platform enables interactions with active users via its customers’ applications, Websites and other digital interfaces. Its platform encompasses the functionalities required for modern customer engagement, which include data ingestion, classification, orchestration, personalization, and action. The Company offers software development kits (SDKs) for installation into customers’ applications on platforms such as Android, iPhone Operating System (iOS) and desktop / mobile Web.

Closing Price
$39.00
Day's Change
-0.45 (-1.14%)
Bid
--
Ask
--
B/A Size
--
Day's High
40.39
Day's Low
38.90
Volume
(Average)
Volume:
497,921

10-day average volume:
525,607
497,921

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

8:00 am ET July 15, 2022 (Globe Newswire) Print

EQNX::TICKER_START (NASDAQ:MXCT),(LSE:MXCT),(LSE:MXCN), EQNX::TICKER_END MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the second quarter of 2022 after the U.S. market close on Wednesday, August 10, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation(R) platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT(TM) platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx(TM), STx(TM) GTx(TM) and VLx(TM); a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser                                +1 415-937-5400
Gilmartin Group                              ir@maxcyte.com
David Deuchler, CFA
Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
UK IR Adviser                                +44 (0)203 709 5700
Consilium Strategic Communications           maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh

https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png

https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png

comtex tracking

COMTEX_410244512/2010/2022-07-15T08:00:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.